This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates '18 View
by Zacks Equity Research
Zoetis (ZTS) beats both earnings and sales estimates in the third quarter of 2018. The company also updates its 2018 outlook.
Zoetis (ZTS) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 7.79% and 1.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Zoetis beats earnings and sales estimates in the third quarter of 2018.
Should You Buy Zoetis (ZTS) Ahead of Earnings?
by Zacks Equity Research
Zoetis (ZTS) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Zoetis (ZTS) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis' (ZTS) diversified product portfolio, global footprint and productive R&D should help drive both top-and bottom-line growth in the third quarter of 2018.
Why the Earnings Surprise Streak Could Continue for Zoetis (ZTS)
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top Research Reports for Pfizer, Caterpillar & Charter Communications
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Pfizer (PFE), Caterpillar (CAT) and Charter Communications (CHTR).
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
5 Best Biotech Stocks to Buy In October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October
Eli Lilly Prices Animal Health Unit IPO at $24 Per Share
by Zacks Equity Research
Lilly (LLY) prices Elanco IPO at $24 per share which is above the expected range of $20-$23 per share.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Coca-Cola, Disney, BHP and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Coca-Cola, Disney, BHP and Zoetis
Top Analyst Reports for Berkshire Hathaway, Coca-Cola & Disney
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), Coca-Cola (KO) and Disney (DIS).
Zoetis (ZTS) Beats on Q2 Earnings & Sales, Updates '18 View
by Zacks Equity Research
Zoetis second-quarter 2018 results exceed both earnings and sales estimates. The company completes the acquisition of Abaxis, Inc.
Zoetis (ZTS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 8.45% and 2.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More
by Zacks Equity Research
Let's see how these pharma/biotech stocks are poised ahead of their scheduled results on Aug 2.
CTLT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
CTLT vs. ZTS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: PayPal, ConocoPhillips, T-Mobile, Zoetis and PACCAR
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PayPal, ConocoPhillips, T-Mobile, Zoetis and PACCAR
Top Stock Reports for PayPal, ConocoPhillips & T-Mobile
by Zacks Equity Research
Today's Research Daily features new research reports on 16 major stocks, including PayPal (PYPL), ConocoPhillips (COP) and T-Mobile (TMUS).
Abaxis (ABAX) and Zoetis Merger Deal Crosses HRS Hurdle
by Zacks Equity Research
With the adoption of Abaxis' (ABAX) point-of-care diagnostic instruments post acquisition, the combined entity's veterinary diagnostics category should grow faster than the animal health industry.
Zoetis (ZTS) Tides Over HSR Hurdle for Abaxis Acquisition
by Zacks Equity Research
Zoetis' (ZTS) waiting period under the HSR Act ends. It is related to its proposed merger with Abaxis for a purchase consideration of roughly $2 billion in aggregate.
CTLT vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CTLT vs. ZTS: Which Stock Is the Better Value Option?
Why Is Zoetis (ZTS) Up 5.7% Since Its Last Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News For May 17, 2018
by Zacks Equity Research
Companies In The News are: FOXA,IQV,ABAX,ZTS,TEVA,BRK.B